Military-Related PTSD and Insomnia: HONORing the Problem

(DGIwire) – Sleep disturbance is one of the most common issues faced by individuals with post-traumatic stress disorder (PTSD). As reported by Military Times, insomnia and nightmares plague the vast majority of those struggling with the disorder; although it is assumed to be high, notes the publication, relatively little is known about the actual prevalence of sleep disturbances in veterans with PTSD.In order to learn more, researchers from the University of Texas Health Science Center at San Antonio and elsewhere recently surveyed more than 100 active-duty service members and published their results in the November 2016 issue of Psychological Trauma. Unsurprisingly, insomnia was the most often reported PTSD symptom prior to treatment, with 92 percent noting some difficulty falling or staying asleep and 69 percent reporting nightmares.

What was surprising, however, was that about three-fourths of service members still reported insomnia as a problem after PTSD treatment and around half still struggled with nightmares, reported the journal. Additionally, for those service members who no longer met criteria for PTSD after successful treatment, more than half continued to report insomnia and 13 percent continued to report problems with nightmares.

“Researchers are increasingly coming to appreciate the role of sleep quality in potential approaches to PTSD treatment,” says Seth Lederman, MD, the CEO of Tonix Pharmaceuticals, which is developing innovative pharmaceutical products to address public health challenges, with its lead program focusing on PTSD. “New PTSD treatments are being studied that specifically address sleep quality as the key to improving overall symptoms.”

Those who were in the military and think they may be affected by PTSD should consider speaking to their doctor about the latest clinical research study involving an investigational new drug as a potential treatment for PTSD, the HONOR study, a Phase 3 clinical research study sponsored by Tonix Pharmaceuticals. At approximately 35 sites across the U.S., about 550 military PTSD patients will receive either the investigational new drug, TNX-102 SL or placebo sublingual tablets, once-daily at bedtime. Based on the encouraging results in an earlier study with TNX-102 SL in a population with military-related PTSD, the U.S. Food and Drug Administration recently granted Breakthrough Therapy designation to TNX-102 SL for the treatment of PTSD.

To protect the subjects’ identities and confidential medical information, the study organizers have obtained a Certificate of Confidentiality from the U.S. Department of Health & Human Services to ensure patients’ identities are shielded from all persons not connected with this clinical research project. The holder of this Certificate of Confidentiality may not be compelled in any Federal, state, or local civil, criminal, administrative, legislative or other proceedings to identify the research subjects.

To see if you or someone you know is pre-qualified to participate in this research study, please access the study website for this ongoing research study, TheHonorStudy.com, and learn more about it at https://clinicaltrials.gov/show/NCT03062540. The HONOR study is open to veterans or those currently serving in any branch of the military or as a military contractor.

Currently there are no satisfactory approved drug treatments for military-related PTSD. The investigational new drug used in the HONOR study represents a new approach to treating the condition. While symptoms of PTSD may improve or worsen while taking part in this study, participation will provide information about the study drug, a new approach to treating PTSD, that might benefit others with the condition in the future.

* TNX-102 SL is an investigational new drug and has not been approved for any indication.

close